

1 QIBA Proffered Protocol to UPICT. CT: Change
2 Measurements in the Volumes of Solid Tumors

3
4 **Running title: QIBA v-CT Protocol for Solid Tumors V2.0**

5
6 **2011.07.28**

7
8 **QIBA Protocol editor's note: Notes from the editors of the QIBA Profile and the**
9 **QIBA Protocol are in deep red font. Reviewers' comments are in the margin.**
10 **Notes and comments will be removed prior to broadcast in pdf format for public**
11 **comment. Comments from the public will follow a form and format prescribed by**
12 **QIBA for all work products.**

13
14 **QIBA Protocol editor's note: This is a draft. No portion of the text has been**
15 **approved by QIBA for release to the public. The purpose of distributing this draft**
16 **is to obtain input from the QIBA Technical Committee and the Extended Pharma**
17 **Imaging Group.**

18
19 **QIBA Protocol editor's note: Some UPICT instructions are retained verbatim *in***
20 ***blue italics* for the purposes of discussion about this draft. They will be removed**
21 **prior to broadcast.**

22
23 **QIBA Protocol editor's note: The Quantitative Imaging Biomarker Alliance (QIBA,**
24 **pronound KEE'- bah) of the Radiological Society of North America (RSNA) will**
25 **"proffer" this image acquisition, processing, and analysis protocol to UPICT (the**
26 **NIH working group for Uniform Protocols for Imaging In Clinical Trials). The**
27 **format has been prescribed by UPICT, and is essentially non-negotiable.**

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81

X. Title of Imaging Protocol

QIBA Proffered Protocol to UPICT. CT: Change Measurements in the Volumes of Solid Tumors

Instructions to Clinical Trialists who are adapting this imaging protocol for inclusion in their Clinical Trial Protocol are shown in italics. All italic text should generally be removed as part of preparing the final protocol text.

0. Executive Summary

This document describes procedures for quantifying longitudinal changes in the volumes of solid tumors with x-ray computed tomography (CT). Compliance with these procedures will meet the claims for precision of measurement described in the corresponding Profile¹ developed by the CT Technical Committee of the Quantitative Imaging Biomarker Alliance (QIBA) of the Radiological Society of North America (RSNA). The QIBA Profile claims that the 95% confidence intervals surrounding the coefficients of variation for repeated measurements of change in tumor volumes can be consistently less than 30% in measurable lesions. Lesions can be classified as measurable providing that the following conditions are met:

- the longest diameter is 10mm or greater
- the tumor possesses sufficient conspicuity to allow its boundaries to be adequately demarcated from surrounding tissue
- the tumor morphology is not unduly complex
- the tumor composition is sufficiently homogeneous, or the various tissue types within a mass can be segmented from each other

¹ <http://qibawiki.rsna.org/index.php?title=Quantitative-CT> (last accessed 31 May 2011)

82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126

1. Context of the Imaging Protocol within the Clinical Trial

1.1. Utilities and Endpoints of the Imaging Protocol

These image acquisition, processing, and analysis procedures are intended for use in patients with cancer who are followed with serial CT scans to assess their responses to treatment. Changes in volume that exceed 30% are highly likely to represent true biological evolution in the health status of a patient. Claims about the precision of measurement hold for patients with solid tumors of sufficient size and conspicuity as described in the corresponding QIBA Profile. In summary, confidence in the claims increases directly with tumor contrast compared to surrounding tissues. When all other factors are equal, precision improves with increasing tumor volume. However, precision decreases with geometric complexity and as tumors invade multiple tissue compartments. Caution is required when masses contain multiple tissue types, such as necrotic debris, fibrotic elements, and fluid-filled spaces.

This protocol is otherwise agnostic about the settings in which the measurements are made and the way the measurements will be used to make decisions. Typical applications include assessing responses to treatment in individual patients starting new therapeutic regimens, and distinguishing between arms of clinical trials.

1.2. Timing of Imaging within the Clinical Trial Calendar

In order to quantify treatment-induced change, the pre-treatment CT scan shall take place prior to any new intervention to treat the disease. This scan is referred to as the “baseline” scan. It should be acquired as closely as possible, but not before, the initiation of treatment, and in no case more than a certain number of days before treatment as specified in the clinical protocol.

In clinical trials, there is an expectation that all patients will have follow up scans acquired at regular, calendar-based intervals specified by the clinical protocol. Otherwise, the QIBA Profile and this derivative imaging protocol does not presume a specific timing.

1.3. Management of Pre-enrollment Imaging

To quantify changes in volume with the precision claimed in the corresponding QIBA Profile, the pre-treatment image acquisition and processing must meet or exceed the minimum specifications described in this document. Images that meet these criteria can serve as “baseline” scans on which change measurements are based. Scans that do not meet minimum specifications must be re-acquired, or the claims will not be valid.

1.4. Management of On-Protocol Imaging Performed Off-Schedule

127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172

This protocol does not presume a universal, or even a specific, imaging schedule. It is intended to measure tumor volume change between two arbitrary time points, including scans that are acquired outside of the protocol-specified time-window (OOW scans).

Management of the clinical trial calendar, deviations from the protocol specified time window, and potential impacts of deviations or non-uniformity of interval timing on derived outcomes such as Time-To-Progression (TTP) or Progression-Free-Survival (PFS) are left to clinical trial protocol owners.

1.5. Management of On-Protocol Imaging Performed Off-Specification

Deviation from the specifications and procedures described in this protocol will likely degrade the quality of measurements. QIBA Profile claims about the precision of measurement only apply when minimum specifications are met.

Management of off-specification imaging, including decisions about whether to accept "suboptimal but readable" scans or to require repeat scans are left to the clinical trial protocol owners.

1.6. Management of Unscheduled, Off-Protocol Imaging

This QIBA proffered imaging protocol is limited to measurements based on CT scans. Alternative imaging technologies may be used as indicators of disease progression only. For example, in a subject with lung cancer who is being followed with CT scans of the body, if an unscheduled, off-protocol MRI scan of the head is acquired in the middle of a cycle to evaluate a new complaint of headache, then it may be read either as confirming progression or being negative for progression depending on whether or not new brain metastases are discovered. In contrast, a high resolution CT scan of the chest acquired to evaluate sudden shortness of breath may be used to assess target lesions in the field of view regardless of whether pulmonary embolism is detected provided that image quality conforms with specifications.

1.7. Subject Selection Criteria Related to Imaging

These procedures are applicable to patients with solid tumors that can be measured with CT. Otherwise, patient selection criteria are left to the authors of the clinical trials that use them.

1.7.1. Relative Contraindications and Mitigations

This protocol involves ionizing radiation. Section 13.1 describes radiation risk and safety considerations, e.g., for young children or pregnant women. Local standards for good clinical practice (cGCP) and the ALARA Principle (As Low As Reasonably Achievable radiation exposure) should be followed.

173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214

215

216
217

This protocol involves the use of intravenous contrast. Section 13.2 describes risk and safety considerations, e.g., for subjects with chronic renal failure. Local standards for good clinical practice (cGCP) should be followed. Procedures for the use of contrast in Section 5 assume there are no known contra-indications in a particular subject.

1.7.2. Absolute Contraindications and Alternatives

There are few, if any, absolute contra-indications to the image acquisition and processing procedures described in this protocol. Local standards for good clinical practice (cGCP) should be followed.

This protocol does not intend to constrain the use of alternative imaging technologies when clinically indicated. However, the measurement of tumor volume with non-CT based imaging technologies is outside the scope of this protocol.

2. Site Selection, Qualification and Training

2.1. Personnel Qualifications

This protocol does not presume specific personnel or qualifications beyond those normally required for the performance and interpretation of CT exams with contrast. Local rules and regulations for the certification of personnel providing patient care should be followed. Responsibilities for the qualification and maintenance of certification of imaging professionals who participate in clinical trials is left to each clinical trial sponsor.

2.2. Imaging Equipment

This protocol requires a CT scanner with the following characteristics:

- multiple rows of detectors
- see Section 7 for required acquisition capabilities
- conforms to the Medical Device Directive Quality System and the Essential Requirements of the Medical Device Directive
- designed and tested for safety in accordance with IEC 601-1, as well as for ElectroMagnetic Compatibility (EMC) in accordance with the European Union's EMC Directive, 89/336/EEC
- labelled for these requirements, as well as ISO 9001 and Class II Laser Product, at appropriate locations on the product and in its literature
- CSA compliant

Measurement Software: See Section 9 for general capabilities requirements.

Participating sites may be required to qualify for, and consistently perform, at a specific level of compliance. (See the discussion of compliance in Appendix C.)

218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265

2.3. Infrastructure

No particular infrastructure or physical environment is specified. It is assumed that imaging procedures will be performed in locations that are in compliance with local regulations for operating medical imaging facilities.

2.4. Quality Control

2.4.1. Procedures

See 12.1.1 for procedures the site must implement and document.

2.4.2. Baseline Metrics Submitted Prior to Subject Accrual

See 12.1.2 for metric submission requirements.

2.4.3. Metrics Submitted Periodically During the Trial

See 12.1.3 for metric submission requirements.

Additional task-specific Quality Control is described in sections below.

2.5. Protocol-specific Training

No UPICT protocol-specific training is specified beyond familiarity with the relevant sections of this document and the QIBA Profile from which it is derived.

3. Subject Scheduling

3.1. Timing Relative to Index Intervention Activity

Timing is left to the discretion of attending physicians in clinical care settings and the owners of clinical trials. Otherwise, calendar based schedules are preferred to cycle based schedules for several reasons:

- Scan schedules can be established at the beginning of the trial, so patients can count on them, and plan their life activities around them.
- They give patients a positive message, namely that their health care providers expect to be working with them for a long time.
- They tend to reduce patient anxiety associated with waiting for scan results before making treatment plans.
- They reduce the work of clinical research coordinators, who can decrease the number of times they engage the radiology scheduling service on behalf of a subject. In fact, they reduce the hassle factor for both site oncology research coordinators and site radiology scheduling services because the farther out they set the schedule, the more degrees of freedom they find on the radiology

266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313

appointment books. If cancellations become necessary, they are easier to achieve than "just in time" additions to the schedule.

- Scientific confounders associated with unequal toxicities, and hence unbalanced time intervals between arms, tend to be reduced.
- Definitive timing allows for direct comparisons between arms based on objective response rates after fixed time intervals, e.g., the magnitude of tumor response at 6 weeks or 12 weeks in each arm.
- Fixed calendar schedules are implemented anyway when patients come off trial for non-progression. It is often best to get this schedule established before the disappointment of coming off trial.

3.2. Timing Relative to confounding Activities (to minimize "impact")

This protocol does not presume any timing relative to other activities. Obviously, locoregional treatments, such as radiation therapy or cryotherapy that occur during a course of chemotherapy will confound assessments of drug-induced changes in tumor volume; however, these maneuvers should not impact the measurements of tumor volume.

3.3. Scheduling Ancillary Testing

This protocol does not depend on any ancillary testing.

4. Subject Preparation

4.1. Prior to Arrival

No preparation is specified beyond the local standard of care for CT with contrast.

4.2. Upon Arrival

4.2.1. Confirmation of subject compliance with instructions

No preparation is specified beyond the local standard of care for CT with contrast.

4.2.2. Ancillary Testing

No ancillary testing is specified beyond the local standard of care for CT with contrast.

4.2.3. Preparation for Exam

No exam preparation is specified beyond the local standard of care for CT with contrast.

5. Imaging-related Substance Preparation and Administration

5.1. Substance Description and Purpose

314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360

The use of contrast is not an absolute requirement for this protocol. However, the use of intravenous and oral contrast materials are often medically indicated for the diagnosis and staging of solid tumors in many clinical settings. Contrast influences the appearance, or conspicuity, of neoplastic masses, and can have an impact on the quantification of solid tumor volumes. Therefore,

- If intravenous contrast was administered during the baseline scan, equivalent contrast shall be used at all subsequent time points. If intravenous contrast was not used at baseline, it shall not be used during follow-up scans.
- If oral contrast was used at baseline, equivalent contrast shall be used at all subsequent time points. If oral contrast was not used at baseline, it shall not be used during follow-up scans.

The professional who acquires the scans shall record the use and type of contrast in the image header.

5.2. Dose Calculation and/or Schedule

Site-specific sliding scales that have been approved by local medical staffs and regulatory authorities shall be used for patients with relative contraindications to contrast, such as impaired renal function (e.g., sliding scale contrast dose reduction based on creatinine clearance).

For a given subject, the same contrast dose should be used for each scan. If a different brand or type of contrast is used, the dose may be adjusted to ensure comparability as indicated and by peer-reviewed literature and/or the contrast manufacturers' package inserts.

5.3. Timing, Subject Activity Level, and Factors Relevant to Initiation of Image Data Acquisition

For a given subject, image acquisition should start at the same time after contrast administration for each scan.

Scan delay after contrast administration is dependent upon both the dose and rate of administration, as well as the type of scanner being used. Contrast administration should be tailored to optimize lesion conspicuity. Generally, since there are multiple concentrations of contrast as well as administration rates and scanning speeds, it is difficult to mandate specific values. Generally, institutional guidelines should be followed so as to optimize reproducibility of the scan technique.

The professional who acquires the scan shall record the actual contrast media dose and administration schedule in the header.

5.4. Administration Route

361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408

Intravenous contrast: The claims hold when the administration of IV contrast meets specifications for uniformity at each time-point. Confidence improves with injection into a large antecubital vein known to be patent from observation of intravenous saline drip, but is not an absolute requirement.

Oral contrast: The claims hold when the same contrast agent is given per os at a constant timing interval prior to image acquisition.

5.5. Rate, Delay and Related Parameters / Apparatus

The claims hold when the administration of IV contrast meets specifications for uniformity at each time-point. The technologist shall ensure that the time-interval between the administration of intravenous contrast (or the detection of bolus arrival) and the start of the image acquisition is the same as for prior scans. Confidence improves with the use of a power injector.

If a different brand or type of intravenous contrast is used, the rate may be adjusted to ensure comparability as documented by peer-reviewed literature and/or the contrast manufacturers' package inserts.

5.6. Required Visualization / Monitoring, if any

The potential for adverse reactions to contrast should be monitored according to the local standard of care. The prevention and management of contrast reactions is outside the scope of this quantitative imaging protocol.

5.7. Quality Control

See 12.2.

6. Individual Subject Imaging-Related Quality Control

See 12.3.

7. Imaging Procedure

7.1. Required Characteristics of Resulting Imaging Data

This section describes characteristics of the acquired images that are important for the quantification of tumor volume. Characteristics not covered here are left to the discretion of the clinical protocol authors and professionals at participating sites.

Additional details about the method for acquiring these images are provided in section 7.2.

7.1.1. Data Content

409
410
411 Imaging data for measurement of tumor volume must be performed on qualified
412 equipment. The QIBA Profile describes compliant devices.

413
414 All serially acquired CT scans for an individual participant shall be performed on the
415 same platform. In the rare instance of equipment malfunction, follow-up scans of an
416 individual patient can be performed on the same type of platform. All efforts shall be
417 made to have the follow-up scans performed with identical parameters. This shall be
418 inclusive of as many of the scanning parameters as possible, including the same field of
419 view (FOV).

420
421 The imaging professional who acquires the images shall set the scan plane to be the
422 same as for prior scans.

423
424 A set of scout images shall be initially obtained. For imaging of the chest, contiguous
425 thin section slices from the thoracic inlet to the adrenal glands shall be obtained during
426 a single breath hold. Pitch shall be chosen so as to allow completion of the scan in a
427 single breath hold. The scanner shall be capable of acquiring the imaging data at an
428 axial rate of at least 4cm per second. In some cases two or more breaths may be
429 necessary. In those cases, it is important that the target lesion be fully included within
430 one of the sequences. For imaging of the abdomen and pelvis, the scan should extend
431 from the apex of the dome of the liver to the pubic symphysis. The axial scan rate
432 requirement can be relaxed for abdominopelvic imaging.

433
434 The imaging professional who acquires the images shall record the actual Anatomic
435 Coverage, Field of View, Scan Duration, and Scan Plane in the header.

436
437 **Field of View** affects pixel size due to the fixed image matrix size used by most CT
438 scanners. The same settings for field of view should be used during each time-point
439 measurement.

440
441
442
443
444
445

7.1.2. Data Structure

The following parameters describe how the data should be acquired:

Parameter	Specification
Scan Duration for Thorax	The Acquisition Device shall be capable of performing the required scans at an axial rate of at least 4cm per second.
Anatomic Coverage	The Technologist shall perform the scan such that the acquired anatomy is the same as for prior scans.
Scan Plane (Image Orientation)	The Technologist shall set the scan plane to be the same as for prior scans.
Total Collimation Width	The Acquisition Device shall be set up so as to achieve a total collimation width ≥ 20 mm.
IEC Pitch	The Acquisition Device shall be set up so as to achieve IEC pitch less than 1.5.
Tube Potential	The Acquisition Device shall be set up so as to achieve same kVp for all scans
Single Collimation Width	The Acquisition Device shall be set up so as to achieve single collimation width ≤ 1.5 mm.

446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472

The imaging professional who acquires the images shall ensure that the following parameters are recorded in the image header: Anatomic Coverage, Field of View, Scan Duration, Scan Plane, Total Collimation Width, Single Collimation Width, Scan Pitch, Tube Potential, and Slice Width.

Informative Text: Comments on Data Sampling Specifications:

mAs (milliamperes of current) is not specified here. Instead, the setting is determined for each CT scanner manufacturer’s model and represented in Model Specific Parameters of Appendix G. This approach allows each manufacturer to may make recommendations on how to best establish operating points for their equipment that meets all requirements simultaneously.

Collimation Width (defined as the total nominal beam width) is often not directly visible in the scanner interface. Wider collimation widths can increase coverage and shorten acquisition, but can introduce cone beam artifacts which may degrade image quality.

Slice intervals (a.k.a. "reconstruction intervals" that result in discontinuous data are unacceptable as they may “truncate” the spatial extent of the tumor, degrade the identification of tumor boundaries, confound the precision of measurement for total tumor volumes, etc.

Slice Width directly affects voxel size along the subject z-axis. Smaller voxels are preferable to reduce partial volume effects and (likely) provide higher precision due to higher spatial resolution.

473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500

501
502
503
504
505
506
507
508
509
510
511
512

Pixel Size directly affects voxel size along the subject x-axis and y-axis. Smaller voxels are preferable to reduce partial volume effects and (likely) provide higher measurement precision.

Isotropic Voxels are expected to improve the reproducibility of tumor volume measurements, since the impact of tumor orientation (which is difficult to control) is reduced by more isotropic voxels.

Scan Plane may differ for some subjects due to the need to position for physical deformities or external hardware, but should be constant for each scan of a given subject.

Faster **Rotation Speed** reduces the breath hold requirements and reduces the likelihood of motion artifacts.

7.1.3. Data Quality

The parameters that describe imaging device characteristics which influence the quality of the images are detailed in the QIBA Profile. Image quality must be uniform at each time-point in order to meet the QIBA Profile claims for precision of measurement when quantifying changes in tumor volumes.

7.2. Imaging Data Acquisition

7.2.1. Subject Positioning

Parameter	Specifications
Subject Positioning	The technologist shall position the subject in the way that the subject was positioned during the prior scans. If the previous positioning is unknown, the technologist shall position the subject Supine/Arms Up/Feet first if possible.
Table Height	The technologist shall adjust the table height to place the mid-axillary line at isocenter.

The imaging professional who acquires the images shall record actual patient positioning and table height in the header:

Informative Text: Comments on Subject Positioning

For a given subject, they may be placed in a different position if medically unavoidable due to a change in clinical status, but otherwise the same positioning should be used for each scan. If possible, that should be Supine/Arms Up/Feet First.

513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557

If the previous positioning is unknown, the subject should be positioned Supine/Arms Up/Feet First if possible. This has the advantage of promoting consistency, and reducing cases where intravenous lines, which could introduce artifacts, go through gantry.

Consistent positioning is required to avoid unnecessary variance in attenuation, changes in gravity induced shape, or changes in anatomical shape due to posture, contortion, etc. Careful attention should be paid to details such as the position of their upper extremities, the anterior-to-posterior curvature of their spines as determined by pillows under their backs or knees, the lateral straightness of their spines, and, if prone, the direction the head is turned.

Factors that adversely influence patient positioning or limit their ability to cooperate (breath hold, remaining motionless, etc.) should be recorded in the corresponding DICOM tags and case report forms, e.g., agitation in patients with decreased levels of consciousness, patients with chronic pain syndromes, etc.

7.2.2. Instructions to Subject During Acquisition

Movement

The technologist shall instruct the patient to remain motionless during the procedure to prevent blurring of the pictures.

Breath Hold

The technologist shall ensure that image acquisition occurs at, or at least near, the height of full inspiration.

The technologist shall ensure that the breath hold state is the same as for prior scans.

Factors that adversely influence patient positioning or limit their ability to cooperate (e.g., breath hold, remaining motionless, agitation in patients with decreased levels of consciousness, patients with chronic pain syndromes, etc.) shall be recorded.

Informative Text: Comments on Instructions to Subjects

Breath holding reduces motion that might degrade the image. Full inspiration inflates the lungs, which separates structures and makes lesions more conspicuous.

Although performing the acquisition in several segments (each of which has an appropriate breath hold state) is possible, performing the acquisition in a single breath hold is likely to be more easily repeatable and does not depend on the technologist knowing where the lesions are located.

558
559
560
561

7.2.3. Timing/Triggers

Parameters	Specifications
Timing / Triggers	The technologist shall ensure that the time-interval between the administration of intravenous contrast (or the detection of bolus arrival) and the start of the image acquisition is the same as for prior scans.

562 The actual Timing and Triggers shall be recorded.

563
564
565

Informative Text: Comments on Timing and Triggers

566 For each subject, the time-interval between the administration of intravenous
567 contrast and the start of the image acquisition should be determined in advance,
568 and then maintained as precisely as possible during all subsequent
569 examinations.

570
571 For lung masses, image acquisition should be timed to coincide with visualization
572 of the thoracic arteries. For sub-diaphragmatic acquisitions, timing should coincide
573 with opacification of the portal-venous blood vessels.

574
575
576

7.2.4. Model-Specific Parameters

577 **Appendix G.1** lists acquisition parameter values for specific models/versions that can
578 be expected to produce data meeting the requirements of Section 7.1.

579
580
581

7.2.5. Archival Requirements for Primary Source Imaging Data

582 See 11.3.

583
584
585

7.3. Imaging Data Reconstruction

586 The following parameters describe general characteristics of the reconstruction:

587

Parameter	Specifications
Reconstruction Field of View	Entire lateral extent of the patient, but no greater than required to image the entire body
Slice Thickness	=<2.5mm
Reconstruction Interval	=<2.5mm
Reconstruction Overlap	> 0 (i.e. no gap, but may have some overlap)
Reconstruction Kernel Characteristics	equivalent for all time points

588
589

590 Actual Spatial Resolution, Noise, Pixel Spacing, Reconstruction Interval, Reconstruction
591 Overlap, Reconstruction Kernel Characteristics, as well as the model-specific
592 Reconstruction Software parameters utilized to achieve compliance with these metrics
593 shall be recorded.

594
595

Informative Text: Comments on Data Reconstruction

596
597

Spatial Resolution quantifies the ability to resolve spatial details. Lower spatial resolution can make it difficult to accurately determine the borders of tumors, and as a consequence, decreases the precision of volume measurements. Increased spatial resolution typically comes with an increase in noise. Therefore, the choice of factors that affect spatial resolution typically represent a balance between the need to accurately represent fine spatial details of objects (such as the boundaries of tumors) and the noise within the image. Spatial resolution is mostly determined by the scanner geometry (which is not usually under user control) and the reconstruction kernel (which is somewhat under user control as the user usually gets to choose from a limited set of choices of reconstruction kernels provided at the scanner). It is stated in terms of “the number of line-pairs per cm that can be resolved in a scan of resolution phantom (such as the synthetic model provided by the American College of Radiology and other professional organizations).” –OR– “the full width at half of the line spread function”.

611
612

Reconstruction Field of View affects reconstructed pixel size because the fixed image matrix size of most CT scanners is 512 X 512. If it is necessary to expand the field of view to encompass more anatomy, the resulting larger pixels may be less than is necessary to achieve the claim. A targeted reconstruction with a smaller field of view may be necessary, but a reconstruction with that field of view would need to be performed for every time point. Pixel Size directly affects voxel size along the subject x-axis and y-axis. Smaller voxels are preferable to reduce partial volume effects and provide higher measurement precision. Pixel size in each dimension is not the same as resolution in each dimension; inherent resolution is different than how the data is reconstructed and is strongly affected by the reconstruction kernel. It is important not to throw away resolution to match the worse to the better.

624
625

Reconstruction Interval (a.k.a. Slice spacing) that results in discontinuous data is unacceptable as they may “truncate” the spatial extent of the tumor, degrade the identification of tumor boundaries, confound the precision of measurement for total tumor volumes, etc. Decisions about overlap (having an interval that is less than the nominal reconstructed slice thickness) need to consider the technical requirements of the clinical trial, including effects on measurement, throughput, image analysis time, and storage requirements. Reconstructing datasets with overlap will increase the number of images and may slow down throughput, increase reading time and increase storage requirements. For multidetector row CT (MDCT) scanners, creating overlapping image data sets has NO effect on radiation exposure; this is true because multiple reconstructions having different

626
627

628
629

630
631

632
633

634
635

636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682

kernel, slice thickness and intervals can be reconstructed from the same acquisition (raw projection data) and therefore no additional radiation exposure is needed. <Note that the slice thickness is “nominal” since the thickness and is not technically the same at the middle and the edges>

Reconstruction Kernel Characteristics need to be defined to optimize the analysis for each lesion while still meeting the requirements for noise and spatial resolution. A softer kernel can reduce noise at the expense of spatial resolution. An enhancing kernel can improve resolving power at the expense of increased noise.

7.3.1. Device Model-Specific Parameters

Appendix G.2 lists reconstruction parameter values for specific models/versions that can be expected to produce data meeting the requirements of Section 7.1.

7.3.2. Archival Requirements for Reconstructed Imaging Data

See 11.4.

7.3.3. Quality Control

See 12.4.

8. Image Post-processing

No post-processing shall be performed on the reconstructed images sent for image analysis. Such processing, if performed, has the potential to disrupt the consistency of the results.

As described in 7.3 above, scans should be delivered as single stacks of images of uniform slice thickness. When images of anatomical regions are reconstructed at different slice thicknesses, they should not then spliced together as a single whole body scan. Quantification of tumor volume can be confounded unless the images are delivered as separate stacks.

9. Image Analysis

The specific aim of image analysis is to measure the volume of neoplastic tumors at each time-point, and then compute the change in volume. The volume of each measurable lesion shall be quantified as described in this section.

Fluid, blood, necrotic debris, and the like should not be included in the measurement of tumor volume. Procedures for segmenting tissue types within a mass are not described by this UPICT protocol, but should be implemented when technically feasible.

683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729

9.1. Input Data to Be Used

Images that are reconstructed in compliance with Section 7 of this protocol may be used directly, since no other post-processing is specified.

No other data is required for the quantification of tumor volume. Dates of image acquisition must be known to compute rates of tumor growth. The date that a new treatment regimen began must be known to calculate time-intervals to progressive disease events as defined by the clinical protocol.

9.2. Methods to Be Used

Each lesion shall be characterized by determining the boundary of the lesion on all of the slices it is visible. Demarcating the edge of a tumor from the surrounding tissue is referred to as segmentation. Segmentation may be performed automatically by a software algorithm, manually by a human observer using a marking tool, or semi-automatically by an algorithm working with human guidance/intervention.

General specifications for image analysis tools can be found in the corresponding Profile document. See Reference 1. For each method of segmentation and measurement used, precision shall be characterized with one of the methods described in section 9.6.

Methods for adjudicating discordant results are not described in this UPICT protocol. Various systems of adjudication are to be selected by attending physicians and clinical trial sponsors.

9.3. Required Characteristics of Resulting Data

Tumor volume is defined as the sum of all the voxel volumes containing neoplastic tissue within the boundaries of a discrete tumor mass on all the tomographic slices on which it is visible. The units of measure shall be mm³ or mL.

The **Sum of Target Lesion Volumes (SOV)** is a value computed by adding up the volumes of all the target lesion at a given time-point.

The **Baseline** SOV corresponds to the measurements on the pre-treatment scan acquired most closely to, but before the start of treatment.

The **Nadir** SOV is the lowest value for the sum of the volumes of all target lesions since the start of a new treatment. The nadir is the reference value for computing changes in SOV when determining whether progression has occurred.

The following lesions may not be included in the SOV

Non-Measurable Lesions:

730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776

Non-measurable lesions are those that are not suitable for quantitative assessment over time. These include:

1) Neoplastic masses that are too small to measure, because their longest uninterrupted diameter (the greatest distance between any two in-plane pixels) is less than 10 mm or two times the axial slice thickness. Or, neoplastic masses whose volume at baseline is less than 625 mm³. The precision of measurement of small lesions is low, and small absolute errors can lead to relatively large errors in terms of % change.

2) Neoplastic masses whose boundaries cannot be distinguished. This includes masses which cannot be demarcated from surrounding tissue because of inadequate contrast, masses with overly complex morphology, or those with highly heterogeneous tissue composition. A tumor that appears to be measurable on some consecutive slices but whose edges become overly obscure on others should be classified as non-measurable.

3) Other types of lesions that are confidently felt to represent neoplastic tissue, but difficult to quantify in a reproducible manner. These include bone metastases, leptomeningeal metastases, malignant ascites, pleural/pericardial effusions, inflammatory breast disease, lymphangitis cutis/pulmonis, cystic lesions, ill defined abdominal masses, etc.

Non-Target Lesions (NTL):

These are lesions which are followed qualitatively (classified at each visit as absent, present, or showing unequivocal progression). All non-measurable lesions (see above) are automatically non-target lesions. Additionally, if the number of measurable lesions is extremely large, it may be impractical to follow all of them quantitatively. Those that are not selected for quantitative assessment are designated non-target lesions, and followed qualitatively.

9.4. Platform-specific Instructions

Appendix G.4 lists parameter values and/or instructions for specific models/versions that can be expected to produce data meeting the requirements of Section 9.3.

9.5. Archival and Distribution Requirements

See 11.6.

9.6. Quality Control

For all measurements, the coefficients of variation should be characterized, and the 95% confidence interval surrounding them should be calculated. Specific quality

777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825

assurance procedures for estimating variance are not specified in this UPICT protocol. See 12.6 for more details.

10. Image Interpretation

While Analysis is primarily about computation; Interpretation is primarily about judgment. Interpretation may be performed at both the lesional / target level and in the aggregate at the subject level (e.g., in an oncology study each index lesion may be measured in longest diameter during the analysis phase, but in this phase a judgment may be made as to whether there is a new “non-index” lesion; the aggregation of the measured lesions with comparison to previous studies coupled with the judgment as to the presence or absence of a new lesion will result in the RECIST classification at the subject level).

10.1. Input Data to Be Used

Describe required input data and any necessary validation or adjustments which should be performed on it. May also specify data which should not be used until after the clinical trial interpretation is recorded.

(e.g. particular image series or views; before and after processing versions of images to evaluate/validate the effects of processing; analysis results)

The input data for the assessment of measurable lesions include scalar values for each tumor volume, the sum of all measured volumes (SOV) at each time-point, and their corresponding changes with respect to the baseline or nadir.

10.2. Methods to Be Used

Describe how the interpretation should be performed. (For example, definition of key anatomical points or pathology boundaries; scoring scales and criteria such as BIRADS, interpretation schema such as RECIST, related annotations)

QIBA Protocol editor's note: The corresponding QIBA Profile describes a system of metrology. Compliance leads to confidence that time-point changes in a measurable neoplastic mass of >30% are highly likely to represent a true evolution in tumor biology, not measurement noise. Recommendations about patient management decisions that might follow from the measurement of change are outside the scope of the QIBA Profile. There are no response assessment criteria presented in this section for making judgments about multiple tumors within a given patient. QIBA has not yet examined the evidence that leads to recommendations about how to manage patients based on changes in individual tumors or ensembles of metastases within patients.

The qualitative assessment of non-target lesions is not addressed by the QIBA Profile.

826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873

10.3. Required Characteristics of Resulting Data

The results of image analysis should produce confidence that changes >30% are biological, and not simply an artifact of measurement variability.

10.4. Platform-specific Instructions

Appendix G.5 provides instructions for specific models/versions that can be expected to produce data meeting the requirements of Section 10.3.

10.5. Reader Training

Compliance with the QIBA Profile is essential for the claims to be valid. All actors who participate in image acquisition, processing, and analysis must be familiar with the relevant passages of the QIBA Profile that govern their behavior. Otherwise, the issues surrounding reader training, however critical, are nonetheless outside the scope of this imaging protocol.

10.6. Archival Requirements

See 11.7.

10.7. Quality Control

See 12.7.

11. Archival and Distribution of Data

Describe the required data formats, transmission methods, acceptable media, retention periods, ...

(e.g. Is the site required to keep local copies in addition to transmitting to the trial repository? Must all intermediate data be archived, or just final results? At what point may various data be discarded?)

11.1. Central Management of Imaging Data

Communication plans, data transmittal plans, and archiving requirements are left to the owners of the clinical trial protocol or the local standards of care for the treatment of individual patients.

Note: The submission of films for digitization is rarely compliant with the QIBA Profile. When digitized films are submitted, they must contain a ruler or quantification will not be possible.

11.2. De-identification / Anonymization Schema(s) to Be Used

874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920

The de-identification software should be certified as fit-for-purpose by regulatory authorities at both the site of origin and site of receipt.

All personal patient information that is not needed for achieving the specific aims of the trial should be removed. Pre-specified data, such as height, weight, and in some cases, sex, race, or age, may be retained if it is essential for achieving the specific aims of the study and as such has been approved for use by regulatory authorities. Anonymization software should also retain DICOM information regarding slice locations, slice thickness, reconstruction interval, pixel size and FOV.

Data should be transferred to a "quarantine area" of a "safe harbor" for cleaning and certification of de-identification by professional research organizations or trained operators using procedures that have been certified by regulatory authorities at the site of receipt. Quality assurance procedures performed by the recipient should verify that the images that will be submitted for analysis have been properly de-identified. Images that were not properly de-identified prior to receipt by the central archiving facility should be obliterated after assuring that copies conform to quality standards for patient privacy.

11.3. Primary Source Imaging Data

This protocol presumes no archiving the pre-reconstruction image data.

11.4. Reconstructed Imaging Data

Reconstructed images shall be archived locally, formatted as either DICOM CT image objects or DICOM Enhanced CT image objects.

Retention period and policy are left to the Clinical Trial Protocol author or local standards of care.

11.5. Post-Processed Data

No post processing is specified; however, if post-processing is performed, the images shall be archived as DICOM objects as described in 11.4.

11.6. Analysis Results

Segmentation results may be recorded as DICOM Segmentation Objects, or STL Model Files.

The data described in 9.3 may be provided in any of the following formats:

- DICOM SR
- DICOM RTSS

921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966

- DICOM secondary capture

- XLS, CSV, XML

11.7. Interpretation Results

The QIBA Profile claims that changes in tumor volume of >30% are likely to represent true changes in tumor biology, not measurement error. Otherwise, interpretation of the results is left to the attending physicians taking care of individual patients and/or the owners of the clinical protocol.

12. Quality Control

12.1. QC Associated with the Site

12.1.1. Quality Control Procedures

Describe required procedures and documentation for routine and periodic QC for the site and various pieces of equipment.

The imaging system and workflow must be compliant with the QIBA Profile. Otherwise, details are left to the local institution or the owners of the clinical trial protocol.

12.1.2. Baseline Metrics Submitted Prior to Subject Accrual

List required baseline metrics and submission details.

The imaging system and workflow must be compliant with the QIBA Profile. Procedures for site qualification are left to the owners of the clinical trial protocol.

12.1.3. Metrics Submitted Periodically During the Trial

List required periodic metrics and submission details.

None specified. Details are left to the local institution or the owners of the clinical trial protocol.

12.2. QC Associated with Imaging-related Substance Preparation and Administration

None specified. Details are left to the local institution or the owners of the clinical trial protocol.

12.3. QC Associated with Individual Subject Imaging

967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013

Acquisition System Calibration: The QA/QC program shall be designed consistent with the goals of the clinical trial. This program may include (a) elements to verify that sites are performing the specified protocol correctly, and (b) elements to verify that sites' CT scanner(s) is (are) performing within specified calibration values. These may involve additional phantom testing that address a limited set of issues primarily relating dose and image quality (such as water calibration and uniformity). This phantom testing may be done in addition to the QA program defined by the device manufacturer as it evaluates performance that is specific to the goals of the clinical trial.

12.3.1. Phantom Imaging and/or Calibration

None specified. Details are left to the local institution or the owners of the clinical trial protocol.

12.3.2. Quality Control of the Subject Image and Image Data

Acknowledged as mission critical, but not specified by the QIBA Profile. Details are left to the local institution or the owners of the clinical trial protocol.

12.4. QC Associated with Image Reconstruction

Acknowledged as mission critical, but not specified by the QIBA Profile. Details are left to the local institution or the owners of the clinical trial protocol.

12.5. QC Associated with Image Processing

Acknowledged as mission critical, but not specified by the QIBA Profile. Details are left to the local institution or the owners of the clinical trial protocol.

12.6. QC Associated with Image Analysis

Acknowledged as mission critical, but not specified by the QIBA Profile. Details are left to the local institution or the owners of the clinical trial protocol.

12.7. QC Associated with Interpretation

Acknowledged as mission critical, but not specified by the QIBA Profile. Details are left to the local institution or the owners of the clinical trial protocol.

13. Imaging-associated Risks and Risk Management

13.1. Radiation Dose and Safety Considerations

It is recognized that X-ray CT uses ionizing radiation. Exposure to radiation poses some risks to the patients. Acceptable levels of risk should be based on the relative

1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041

benefits of acquiring the images, and factor in parameters such as age and disease status (e.g., known disease or screening populations).

13.2. Imaging Agent Dose and Safety Considerations

Acknowledged, but not specified by the QIBA Profile. Details are left to the local institution or the owners of the clinical trial protocol.

13.3. Imaging Hardware-specific Safety Considerations

Acknowledged, but not specified by the QIBA Profile. Details are left to the local institution or the owners of the clinical trial protocol.

13.4. Management and Reporting of Adverse Events Associated with Imaging Agent and Enhancer Administration

None specified by the QIBA Profile. Compliance with local regulations and the standard of care is assumed. Compliance with regulatory requirements for reporting adverse events during a clinical trial as specified by a sponsor is assumed.

13.5. Management and Reporting of Adverse Events Associated with Image Data Acquisition

None specified by the QIBA Profile. Compliance with local regulations and the standard of care is assumed. Compliance with regulatory requirements for reporting adverse events during a clinical trial as specified by a sponsor is assumed.

1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073

Appendix A: Acknowledgements and Attributions

This imaging protocol is proffered by the Radiological Society of North America (RSNA) Quantitative Imaging Biomarker Alliance (QIBA) Volumetric Computed Tomography (v-CT) Technical Committee.

The v-CT technical committee is composed of scientists representing the imaging device manufacturers, image analysis software developers, image analysis laboratories, biopharmaceutical industry, academia, government research organizations, professional societies, and regulatory agencies, among others. All work is classified as pre-competitive. A more detailed description of the v-CT group and its work can be found at the following web link: http://qibawiki.rsna.org/index.php?title=Volumetric_CT

Contributors to this imaging protocol from the Volumetric CT Technical Committee included the following people (in alphabetical order):

QIBA Protocol editor's note: No one has yet endorsed this protocol.

Contributors to this imaging protocol from the Extended Pharma Imaging Group included the following people (in alphabetical order):

QIBA Protocol editor's note: No one has yet endorsed this protocol. If you or your organization want to sign on, then please inform the editor by e-mailing mozley@merck.com

The v-CT Committee is deeply grateful for the remarkable support and technical assistance provided by the staff of the Radiological Society of North America.

1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102

Appendix B: Background Information

The long-term goal of the v-CT technical committee is to qualify the quantification of tumor volumes with x-ray computed tomography (CT) as a biomarker of response to treatment.

The specific aim of this image acquisition and processing protocol is to describe procedures that seem sufficient for quantifying the volumes of neoplastic masses that have relatively simple geometric shapes and are adequately demarcated from surrounding non-neoplastic tissues. This particular image acquisition and processing protocol is limited to masses that have measurable, in-plane, longest diameters of 10 mm or more. The basis for this limit is referenced in the corresponding QIBA Profile. Briefly, the surface area to volume ratio becomes too small in tumors with a longest diameter of less than 10 mm. The QIBA Profile on which this protocol is based claims that following these image acquisition and processing procedures will produce volume measures with a 95% confidence interval of less than 30%.

The protocol describes, in predominantly chronological order, procedures that are required to achieve this level of precision.

The protocol describes procedures that should be universally followed in this setting, regardless of the instrument that is used to acquire the data. It also provides links to tables that list specific settings on various makes-and-models of CT scanners.

This protocol should be considered for use in the care of individual patients in conventional medical settings, as well as in clinical trials of new therapies for solid tumors.

1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135

Appendix C: Conventions and Definitions

Acquisition vs. Analysis vs. Interpretation

This document organizes acquisition, reconstruction, post-processing, analysis and interpretation as sequential steps in a workflow that transforms data to information to knowledge.

Acquisition, reconstruction and post-processing address the collection and structuring of new data from the subject. Analysis consists of those computational steps that transform the data into information by extracting important values. Interpretation is primarily considered to be judgment that transforms the information into knowledge.

Judgment and the transformation of knowledge into wisdom are beyond the scope of this document.

Other Definitions

Unless explicitly described above or in the corresponding QIBA Profile, QIBA has not yet examined the evidence required to offer any other definitions.

Appendix D: Documents included in the imaging protocol (e.g., CRFs)

Not specified by the QIBA Profile. These are left to the owners of the clinical trial.

Appendix E: Associated Documents (derived from the imaging protocol or supportive of the imaging protocol)

Not specified by the QIBA Profile. These are left to the owners of the clinical trial.

Appendix F: TBD

1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184

Appendix G: Model-specific Instructions and Parameters

For acquisition modalities, reconstruction software and software analysis tools, profile compliance requires meeting the activity specifications above.

This Appendix provides, as an informative tool, some specific acquisition parameters, reconstruction parameters and analysis software parameters that are expected to be compatible with meeting the profile requirements. Just using these parameters without meeting the requirements specified in the profile is not sufficient to achieve compliance. Conversely, it is possible to use different compatible parameters and still achieve compliance.

These settings were determined to be reasonable by the QIBA CT 1C groundwork study team.

Sites using models listed here are encouraged to consider using these parameters for both simplicity and consistency. Sites using models not listed here may be able to devise their own settings that result in data meeting the requirements.

Table Model-specific Parameters for Acquisition Devices

IMPORTANT NOTE: The presence of a product model/version in the table does not imply it has demonstrated compliance with the QIBA Profile. Refer to the QIBA Compliance Statement for the product.

Acquisition Device	Settings Compatible with Compliance	
GE Discovery HD750 sct3	kVp	120
	Number of Data Channels (N)	64
	Width of Each Data Channel (T, in mm)	0.625
	Gantry Rotation Time in seconds	1
	mA	120
	Pitch	0.984
	Scan FoV	Large Body (500mm)
Philips Brilliance IDT mx8000	kVp	120
	Number of Data Channels (N)	16
	Width of Each Data Channel (T, in mm)	0.75
	Gantry Rotation Time in seconds	0.75
	Effective mAs	50
	Pitch	1.0
	Scan FoV	500

1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231

Acquisition Device	Settings Compatible with Compliance		
Philips Brilliance 64	1232	kVp	120
	1233	Number of Data Channels (N)	64
	1234	Width of Each Data Channel (T, in mm)	0.625
	1235	Gantry Rotation Time in seconds	0.5
	1236	Effective mAs	70
	1237	Pitch	0.798
	1237	Scan FoV	500
Siemens Sensation 64	1238	kVp	120
	1239	Collimation (on Operator Console)	64 x 0.6 (Z-flying focal spot)
	1240	Gantry Rotation Time in seconds	0.5
	1241	Effective mAs	100
	1242	Pitch	1.0
	1243	Scan FoV	500
Toshiba Aquilion 64	1245	kVp	120
	1246	Number of Data Channels (N)	64
	1247	Width of Each Data Channel (T, in mm)	0.5
	1248	Gantry Rotation Time in seconds	0.5
	1249	mA	25
	1250	Pitch	.828
	1251	Scan FoV	Medium and Large

1252
1253
1254
1255
1256
1257
1258
1259
1260

Table Model-specific Parameters for Reconstruction Software

IMPORTANT NOTE: The presence of a product model/version in the table does not imply it has demonstrated compliance with the QIBA Profile. Refer to the QIBA Compliance Statement for the product.

Reconstruction Software	Settings Compatible with Compliance	
GE Discovery HD750 sct3	Reconstructed Slice Width, mm	1.25
	Reconstruction Interval	1.0mm
	Display FOV, mm	350
	Recon kernel	STD
Philips	Reconstructed Slice Width, mm	1.00

1261

1262

Reconstruction Software	Settings Compatible with Compliance	
Brilliance 16 IDT mx8000	Reconstruction Interval	1.0mm (contiguous)
	Display FOV, mm	350
	Recon kernel	B
Philips Brilliance 64	Reconstructed Slice Width, mm	1.00
	Reconstruction Interval	1.0mm (contiguous)
	Display FOV, mm	350
	Recon kernel	B
Siemens Sensation 64	Reconstructed Slice Width, mm	1.00
	Reconstruction Interval	1.0mm
	Display FOV, mm	350
	Recon kernel	B30
Toshiba Aquilion 64	Reconstructed Slice Width, mm	1.00
	Reconstruction Interval	1.0mm
	Display FOV, mm	350
	Recon kernel	FC11

1263

1264

1265

1266

Table Model-specific Parameters for Image Analysis Software

1267

1268

IMPORTANT NOTE: The presence of a product model/version in the table does not imply it has demonstrated compliance with the QIBA Profile. Refer to the QIBA Compliance Statement for the product.

1269

1270

1271

Image Analysis Software	1288 1289 1290 1291 1292	Settings Compatible with Compliance	
Siemens LunCARE	1293	a	<settings to achieve...>
	1294	b	<settings to achieve...>
	1295	c	<settings to achieve...>
	1296	d	<settings to achieve...>
GE Lung VCAR	1297	e	<settings to achieve...>
	1298	f	<settings to achieve...>
	1299	g	<settings to achieve...>
	1300 1301	h	<settings to achieve...>

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

QIBA v-CT Protocol for Solid Tumors V1.0.2 (continued)

1302
1303
1304

1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331

Image	1332		
Analysis	1333		
Software	1334	Settings Compatible with Compliance	
	1335		
	1336		
R2	1337	i	<settings to achieve...>
ImageChamber	1338	j	<settings to achieve...>
CT Lung	1339	k	<settings to achieve...>
System	1340	l	<settings to achieve...>
	1341		
	1342	m	<settings to achieve...>
Definiens	1343	n	<settings to achieve...>
(name specific	1344	o	<settings to achieve...>
product)	1345	p	<settings to achieve...>
	1346		
	1347	q	<settings to achieve...>
Median (name	1348	r	<settings to achieve...>
specific	1349	s	<settings to achieve...>
product)	1350	t	<settings to achieve...>
	1351		
	1352	u	<settings to achieve...>
Intio (name	1353	v	<settings to achieve...>
specific	1354	w	<settings to achieve...>
product)	1355	x	<settings to achieve...>